Labcorp Expands MRD Testing Portfolio and Reaffirms Dividend Amidst Oncology Innovation Story

Labcorp Holdings declared a quarterly cash dividend of $0.72 per share and expanded its Plasma Detect molecular residual disease portfolio with highly sensitive ctDNA tests for breast, lung, and colon cancers. The dividend reaffirmation and MRD portfolio expansion do not significantly change the focus on execution in core labs and the risk of reimbursement and pricing pressure.